Evicenter
P&T meetings

Lirafugratinib (Lyrfigtu)

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008
Regulatory submission
NDA submitted January 2026
Last updated
158 sources

Economic information and modeling reportBudget impact modelResults

Base case

6 evidence topics · 8 sources

Budget impact model of lirafugratinib: base-case results

No evidence found.

Base-case results of United States cost-effectiveness analyses in advanced biliary tract cancer

“ICER was US $381,864/QALY from the US payer perspective and US $367,609/QALY from the Chinese payer perspective.” (opens the source at this quote in a new tab)

“PPPM all-cause costs increased across treatment lines: 1L US $19,589, 2L US $22,617, and 3L US $33,534” (opens the source at this quote in a new tab)

“Mean cost per patient-month was US $7743 (medical services US $6685; drug costs US $1058); median OS was 5.3 months” (opens the source at this quote in a new tab)

“In the US, this treatment was not cost-effective, resulting in an improvement in effectiveness of 0.144 QALYs and an increase in overall cost of $141,000 (ICER of $976,925).” (opens the source at this quote in a new tab)

Base-case budget impact of pemigatinib in Canada

“Based on public list prices, Pemazyre is estimated to cost the public drug plans approximately $64 million over the next 3 years. However, the actual budget impact is uncertain.” (opens the source at this quote in a new tab)

“Based on the CDA-AMC reanalyses, the budget impact from the introduction of pemigatinib is expected to be $18,571,801 in year 1, $21,113,817 in year 2, and $23,920,712 in year 3 for a 3-year total of $63,606,331.” (opens the source at this quote in a new tab)

“This is likely an underestimation of the true budget impact, as costs for patients who remain on pemigatinib for more than 1 year are not captured.” (opens the source at this quote in a new tab)

Base-case cost-effectiveness of pemigatinib in Canada

“In CDA-AMC reanalyses, the incremental cost-effectiveness ratio for pemigatinib relative to ASC alone and mFOLFOX plus ASC was estimated to be $252,718 and $261,226 per quality-adjusted life-year (QALY) gained, respectively, using the sponsor-submitted price for pemigatinib and publicly listed price for all other drugs.” (opens the source at this quote in a new tab)

“Pemigatinib was therefore not considered cost-effective at a $50,000 per QALY gained willingness-to-pay threshold.” (opens the source at this quote in a new tab)

Base-case cost-effectiveness of pemigatinib from the Taiwanese payer perspective

“Pemigatinib was associated with a 0.59 QALY increase with incremental costs of NT$3,428,442 and a 0.68 QALY increase with incremental costs of NT$3,653,100, yielding an ICER of NT$5,814,700 per QALY and an ICER of NT$5,380,241 per QALY compared to mFOLFOX and 5-FU, respectively (Table 2).” (opens the source at this quote in a new tab)

“Based on the updated efficacy data from pivotal trials, the base-case CEA results over a lifetime (Table 2) showed that compared to mFOLFOX, pemigatinib resulted in an incremental QALY of 1.20, additional costs of US$99,762, and an ICER of US$83,475 per QALY.” (opens the source at this quote in a new tab)

“Compared to 5-FU/LV, pemigatinib had an incremental QALY of 1.27, additional costs of US$107,186, and an ICER of US$84,386 per QALY.” (opens the source at this quote in a new tab)

“Both ICERs were below the WTP threshold (US$97,048), with INMB values of US$16,221 (mFOLFOX) and US$16,083 (5-FU/LV).” (opens the source at this quote in a new tab)

“The new regimen provided an incremental 0.13 quality-adjusted life-years, with incremental costs of NT$459,697, yielding an incremental cost-effectiveness ratio of NT$3,411,098 per quality-adjusted life-year and an incremental net monetary benefit of - NT$70,268.” (opens the source at this quote in a new tab)

Base-case costs and outcomes of the Taiwanese cost-effectiveness analysis of a biomarker-driven pemigatinib regimen
Estimate, 2021 NT$Current regimen (fluorouracil)New regimen (pemigatinib or mFOLFOX by FGFR2 status)
Total cost“524,472”“984,168”
Genetic testing fee“0”“30,000”
Medication cost“63,430”“387,176”
Non-medication cost“305,799”“378,437”
Total cost of progressed disease state“155,243”“188,555”
OutcomeCurrent regimen (fluorouracil)New regimen (pemigatinib or mFOLFOX by FGFR2 status)Incremental change
Life-years, overall“0.67”“0.86”“0.19”
QALYs, overall“0.47”“0.61”“0.13”

“The new regimen was found to be 53.2% cost effective in the probabilistic sensitivity analysis. The expected value of uncertainty measured by the expected value of perfect information was NT$80,695/person.” (opens the source at this quote in a new tab)

Base-case cost-effectiveness of pemigatinib from Greek and United States perspectives

“Furthermore, pemigatinib appeared to yield more QALYs gained versus mFOLFOX+ASC and ASC alone (1.66 vs 0.44 and 0.41, respectively), resulting in ICERs of €69,928 per QALY gained and €46,626 per LY gained versus mFOLFOX+ASC and €69,345 per QALY gained and €45,935 per LY gained compared to ASC alone.” (opens the source at this quote in a new tab)

“We calculated pemigatinib’s PFS ICER to be $127,127 and OS ICER to be $183,628.” (opens the source at this quote in a new tab)